ArticleHospital pediatrics2021

A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment.

Scarlett Carmen Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.